Global antiplatelet sales trend: A focus on P2Y12 inhibitors from 2008 to 2018
Background: P2Y12 inhibitors are an important component of dual antiplatelet therapy. Yet, their accessibility and affordability across countries stratified by income levels have not been studied. Methods: Sales data were retrieved from the IQVIA Multinational Integrated Data Analysis System for the...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-04-01
|
| Series: | American Heart Journal Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666602221000185 |
| _version_ | 1811331339575623680 |
|---|---|
| author | Xuxiao Ye Jessica J.P. Shami Vincent K.C. Yan Wei Kang Joseph E. Blais Jiaxi Zhao Wallis C.Y. Lau Li Wei Ian C.K. Wong Esther W. Chan |
| author_facet | Xuxiao Ye Jessica J.P. Shami Vincent K.C. Yan Wei Kang Joseph E. Blais Jiaxi Zhao Wallis C.Y. Lau Li Wei Ian C.K. Wong Esther W. Chan |
| author_sort | Xuxiao Ye |
| collection | DOAJ |
| description | Background: P2Y12 inhibitors are an important component of dual antiplatelet therapy. Yet, their accessibility and affordability across countries stratified by income levels have not been studied. Methods: Sales data were retrieved from the IQVIA Multinational Integrated Data Analysis System for the description of P2Y12 inhibitors global sales. Countries were stratified into 38 high-income countries and 27 middle-income countries. Results: Global sales of P2Y12 inhibitors increased from 0.80 SU per year per person in 2008 to 1.79 in 2018. Growth in sales of P2Y12 inhibitors was greater in middle-income countries compared to high-income countries. Clopidogrel had the highest sales volume in both high-income and middle-income countries from 2008 to 2018, while ticagrelor sales volume increased mainly in high-income countries. Conclusions: Despite current guideline recommendations favoring ticagrelor and prasugrel for the prevention of atherothrombotic complications in patients with an acute coronary syndrome, clopidogrel retained the highest sales volume among the P2Y12 inhibitors from 2008 to 2018. |
| first_indexed | 2024-04-13T16:18:06Z |
| format | Article |
| id | doaj.art-51987162d94149e1a598e7588b0a60db |
| institution | Directory Open Access Journal |
| issn | 2666-6022 |
| language | English |
| last_indexed | 2024-04-13T16:18:06Z |
| publishDate | 2021-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Heart Journal Plus |
| spelling | doaj.art-51987162d94149e1a598e7588b0a60db2022-12-22T02:40:00ZengElsevierAmerican Heart Journal Plus2666-60222021-04-014100020Global antiplatelet sales trend: A focus on P2Y12 inhibitors from 2008 to 2018Xuxiao Ye0Jessica J.P. Shami1Vincent K.C. Yan2Wei Kang3Joseph E. Blais4Jiaxi Zhao5Wallis C.Y. Lau6Li Wei7Ian C.K. Wong8Esther W. Chan9Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative RegionCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative RegionCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative RegionCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative RegionCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative RegionCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative RegionCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region; Laboratory of Data Discovery for Health, Hong Kong Special Administrative Region; Research Department of Practice and Policy, UCL School of Pharmacy, London, UKLaboratory of Data Discovery for Health, Hong Kong Special Administrative Region; Research Department of Practice and Policy, UCL School of Pharmacy, London, UKCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region; Laboratory of Data Discovery for Health, Hong Kong Special Administrative Region; Research Department of Practice and Policy, UCL School of Pharmacy, London, UK; Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, ChinaCentre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong Special Administrative Region; Laboratory of Data Discovery for Health, Hong Kong Special Administrative Region; Department of Pharmacy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, China; Corresponding author at: Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, General Office, L02-56 2/F, Laboratory Block LKS Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong Special Administrative Region.Background: P2Y12 inhibitors are an important component of dual antiplatelet therapy. Yet, their accessibility and affordability across countries stratified by income levels have not been studied. Methods: Sales data were retrieved from the IQVIA Multinational Integrated Data Analysis System for the description of P2Y12 inhibitors global sales. Countries were stratified into 38 high-income countries and 27 middle-income countries. Results: Global sales of P2Y12 inhibitors increased from 0.80 SU per year per person in 2008 to 1.79 in 2018. Growth in sales of P2Y12 inhibitors was greater in middle-income countries compared to high-income countries. Clopidogrel had the highest sales volume in both high-income and middle-income countries from 2008 to 2018, while ticagrelor sales volume increased mainly in high-income countries. Conclusions: Despite current guideline recommendations favoring ticagrelor and prasugrel for the prevention of atherothrombotic complications in patients with an acute coronary syndrome, clopidogrel retained the highest sales volume among the P2Y12 inhibitors from 2008 to 2018.http://www.sciencedirect.com/science/article/pii/S2666602221000185P2Y12 inhibitorsSales trendsIncome levelAntiplateletsDrug utilization |
| spellingShingle | Xuxiao Ye Jessica J.P. Shami Vincent K.C. Yan Wei Kang Joseph E. Blais Jiaxi Zhao Wallis C.Y. Lau Li Wei Ian C.K. Wong Esther W. Chan Global antiplatelet sales trend: A focus on P2Y12 inhibitors from 2008 to 2018 American Heart Journal Plus P2Y12 inhibitors Sales trends Income level Antiplatelets Drug utilization |
| title | Global antiplatelet sales trend: A focus on P2Y12 inhibitors from 2008 to 2018 |
| title_full | Global antiplatelet sales trend: A focus on P2Y12 inhibitors from 2008 to 2018 |
| title_fullStr | Global antiplatelet sales trend: A focus on P2Y12 inhibitors from 2008 to 2018 |
| title_full_unstemmed | Global antiplatelet sales trend: A focus on P2Y12 inhibitors from 2008 to 2018 |
| title_short | Global antiplatelet sales trend: A focus on P2Y12 inhibitors from 2008 to 2018 |
| title_sort | global antiplatelet sales trend a focus on p2y12 inhibitors from 2008 to 2018 |
| topic | P2Y12 inhibitors Sales trends Income level Antiplatelets Drug utilization |
| url | http://www.sciencedirect.com/science/article/pii/S2666602221000185 |
| work_keys_str_mv | AT xuxiaoye globalantiplateletsalestrendafocusonp2y12inhibitorsfrom2008to2018 AT jessicajpshami globalantiplateletsalestrendafocusonp2y12inhibitorsfrom2008to2018 AT vincentkcyan globalantiplateletsalestrendafocusonp2y12inhibitorsfrom2008to2018 AT weikang globalantiplateletsalestrendafocusonp2y12inhibitorsfrom2008to2018 AT josepheblais globalantiplateletsalestrendafocusonp2y12inhibitorsfrom2008to2018 AT jiaxizhao globalantiplateletsalestrendafocusonp2y12inhibitorsfrom2008to2018 AT walliscylau globalantiplateletsalestrendafocusonp2y12inhibitorsfrom2008to2018 AT liwei globalantiplateletsalestrendafocusonp2y12inhibitorsfrom2008to2018 AT ianckwong globalantiplateletsalestrendafocusonp2y12inhibitorsfrom2008to2018 AT estherwchan globalantiplateletsalestrendafocusonp2y12inhibitorsfrom2008to2018 |